

Testicular (Germ Cell) Cancer Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ Pathology: _____

Stage: I IA IB IIA IIB IIC IIIA IIIB IIIC IV Recurrent

Line of Treatment: Neoadjuvant/Pre-Op Adjuvant/Post-Op First Line Second Line Third Line Third Line+ Maintenance

ECOG Performance Status: 0 1 2 3 4

Biomarkers:

Platinum-refractory or resistant? Yes No Not Reported

Seminoma | Stage II-III A | Primary Therapy

BEP: bleomycin, etoposide (Toposar), and cisplatin

EP: etoposide (Toposar) and cisplatin

Seminoma | Stage III B-C | Good and Intermediate Risk | and Metastatic Disease

BEP: bleomycin, etoposide (Toposar), and cisplatin †

Nonseminoma | Stage II-III A | Primary Therapy

BEP: bleomycin, etoposide (Toposar), and cisplatin

EP: etoposide (Toposar) and cisplatin

Nonseminoma | Stage III B-C | Primary Therapy

BEP: bleomycin, etoposide (Toposar), and cisplatin

Nonseminoma | Adjuvant Therapy after RPLND*

EP: etoposide (Toposar) and cisplatin

† BEP is typically given for 3 cycles in good risk seminoma, and 4 cycles in intermediate risk

*RPLND: Retroperitoneal Lymph Node Dissection

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

